Connect with us

Health

Report: Peptide Hydrogels Can Treat Traumatic Brain Injury

mm

Published

on

Traumatic brain injury is a bump, blow or jolt to the head that affects normal brain functions. This injury has sent 2.5 million people in the US to the emergency rooms in 2014. Recently, researchers have made a report on self-assembling peptide hydrogel that was injected into brains of the rats with TBI. The gel has increased blood vessel regrowth and neuronal survival in the rats. After seeing the effective results in the rat test, the researchers have decided to present their report’s result at the American Chemical Society (ACS) 2019 national meeting and exposition.

Biplab Sarkar, Ph.D. who is presenting the report at the meeting, said, “When we think about traumatic brain injuries, we think of soldiers and athletes. But most TBIs actually happens when people fall or are involved in motor vehicle accidents. As the average age of the country continues to rise, the number of fall-related accidents, in particular, will also increase. We saw some indications that the rats in the treated group were more ambulatory than those in the control group, but we need to do more experiments to actually quantify that.”

There are also some other reports which say USA Peptides products can treat many disorders and irregular functionality in our body. The next step of the researchers is to study the behavior of the treated animals to know about their recovery process from TBI. The researchers are also looking to treat rats with a combination of a previously produced angiogenic peptide to enhance the recovery process.

Michelle has been a part of the journey ever since Bigtime Daily started. As a strong learner and passionate writer, she contributes her editing skills for the news agency. She also jots down intellectual pieces from categories such as science and health.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

BioLongevity Labs: How Two Biohackers Are Making Longevity Safe for the Mainstream

mm

Published

on

Humans have been looking for ways to extend their lifespan for hundreds of years. Medicine has made impressive strides, but for many, the effects of aging are still painfully real.

Through BioLongevity Labs, biohackers and entrepreneurs Jay Campbell and Josh Felber aim to introduce ordinary people to potentially life-changing compounds called peptides. Campbell and Felber come from very different backgrounds.

Campbell is a five-time international bestselling author and globally recognized leader in the health-optimization space. Felber is a serial entrepreneur who excels at scaling businesses.

For both men, BioLongevity Labs is more than just a business venture — it’s about helping everyday people discover something that just might prolong and improve their lives.

“Your body inevitably changes as the years pile on,” says Campbell. “Your energy drops, and wrinkles start showing up uninvited. Peptides can change everything.”

Many people have probably heard the term “peptide” in passing. Some may know they’re associated with longevity. Most people just don’t have a strong grasp of how they work.

A peptide is a short chain of amino acids, which are the building blocks of proteins. Essentially, peptides are like shorter, simpler proteins. That might sound unremarkable, but the real magic of peptides lies in how they work.

They function as signaling or “messenger” molecules telling the body to perform specific functions. Many peptides function similarly to hormones. A relevant example is GLP-1 (glucagon-like peptide-1) receptor agonists. This class of medications includes semaglutide and tirzepatide, two wildly popular weight-loss drugs.

“These peptides aren’t just another biohacking fad,” Campbell explains. “They enhance insulin secretion and suppress glucagon release to balance blood sugar levels and promote sustainable weight loss”. But what sets GLP-1 receptor agonists apart is their ability to regulate hunger.

Through the reduction of appetite and increased feelings of fullness, it is far easier for dieters to stick to a calorie deficit.” Although GLP-1 receptor agonists are widely prescribed, most peptides aren’t.

Campbell asserts, because many peptides have the potential to cure illnesses by treating the fundamental root cause, they go against America’s “sick care” model of healthcare. They potentially threaten drug companies and their bottom line.

“Peptides are simultaneously a dream come true for mankind and the worst possible nightmare for the pharmaceutical industry,” says Campbell. “It’s not a conspiracy theory. It’s pure economics and psychology in action. People will do whatever it takes to make as much money as possible in a free-market society, even if it means suppressing a superior solution.”

Patients probably aren’t going to be introduced to peptides through the healthcare system. Many discover them on their own. But for the many people who don’t have a solid understanding of how they work molecularly or even what dose to take, there is a risk. That’s precisely what BioLongevity Labs’ co-founders are attempting to address.

Jay Campbell has dedicated his life to educating people about therapeutic peptides and optimized hormones, and along with his partner Josh Felber, they’ve created a company offering filler-free, third-party tested peptides and bioregulators.

Campbell and Felber stress the fact that BioLongevity Labs isn’t meant to be a replacement for traditional medical care. Instead, its products bridge the gap between clinical and extra-clinical care. There’s no magic pill or single solution to solve the problem of aging.

But thanks to the development of specialized peptides, bioregulators, and small molecules, we’re closer than we’ve ever been before.

Continue Reading

Trending